Provides non-GLP-1 pathways for chronic weight management when eligibility, contraindications, side effects, cost and long-term adherence are considered together.
WEIGHT & METABOLIC HEALTH / PRACTITIONER-GUIDED
Other weight-management medications
GLP-1 drugs are not the only evidence-based option: phentermine/topiramate, naltrexone/bupropion and orlistat may fit selected patients after individualized screening.Create account & prepare for review →Practitioner review required · A prescription is never guaranteed.
FDA-approved products have human efficacy data for defined chronic weight-management indications; benefits and risks differ substantially by drug.
Prescription or OTC depending on product; indication and formulation specific
WHO MAY BE CONSIDERED
Eligibility starts with your complete health context.
- ✓A chronic weight-management indication is established
- ✓A GLP-1 medicine is not preferred, tolerated or accessible
- ✓Blood pressure, pregnancy potential, mental health, seizure and medication history can be reviewed
WHAT A PRACTITIONER REVIEWS
The information that shapes the decision.
- →Weight history, BMI and weight-related conditions
- →Blood pressure, heart rate, mood, seizure and glaucoma history
- →Pregnancy plans, current medicines and prior treatment response
IMPORTANT SAFETY INFORMATION
Reasons treatment may not be appropriate.
- !Phentermine-containing products can raise heart rate and blood pressure and have controlled-substance considerations.
- !Naltrexone/bupropion is incompatible with opioid use and has seizure, blood-pressure and psychiatric warnings.
- !Orlistat causes GI effects and can affect absorption of fat-soluble vitamins and some medicines.
ORIGINAL SOURCES